Early Use of Biologics Reduces Healthcare Costs in Crohn's Disease: Results from a United States Population-Based Cohort.

[1]  S. Ng,et al.  Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. , 2021, Gastroenterology.

[2]  Siddharth Singh,et al.  Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. , 2020, Inflammatory bowel diseases.

[3]  C. Lin,et al.  Association Between Steroid-Sparing Therapy and the Risk of Perianal Fistulizing Complications Among Young Patients With Crohn Disease , 2020, JAMA network open.

[4]  G. Rogler,et al.  Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. , 2020, Gastroenterology.

[5]  J. Colombel,et al.  Systematic review and meta‐analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease , 2020, Alimentary pharmacology & therapeutics.

[6]  M. Murad,et al.  Early vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. , 2020, Inflammatory bowel diseases.

[7]  Zhaohui J. Cai,et al.  Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States , 2020, Clinical and translational gastroenterology.

[8]  G. Kaplan,et al.  Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. , 2020, The American journal of gastroenterology.

[9]  G. Rogler,et al.  Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease. , 2019, Journal of Crohn's & colitis.

[10]  G. Kaplan,et al.  Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study , 2019, Gut.

[11]  M. Regueiro,et al.  The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation , 2019, Inflammatory bowel diseases.

[12]  J. Colombel,et al.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease. , 2019, Inflammatory bowel diseases.

[13]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization , 2018, Journal of the Canadian Association of Gastroenterology.

[14]  P. Kawalec,et al.  Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland , 2018, Front. Pharmacol..

[15]  G. Angelini,et al.  Statistical primer: propensity score matching and its alternatives† , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  M. Cottone,et al.  P387 The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience. , 2017, Journal of Crohn's & colitis.

[17]  G. Kaplan,et al.  Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[18]  S. Ng,et al.  Development of an index to define overall disease severity in IBD , 2016, Gut.

[19]  Dylan S. Small,et al.  The use of bootstrapping when using propensity-score matching without replacement: a simulation study , 2014, Statistics in medicine.

[20]  J. Lindsay,et al.  A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease , 2013, Alimentary pharmacology & therapeutics.

[21]  D. Rubin,et al.  Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data , 2012, Inflammatory bowel diseases.

[22]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[23]  G. D'Haens.  Top-down therapy for IBD: rationale and requisite evidence , 2010, Nature Reviews Gastroenterology &Hepatology.

[24]  N. Abraham,et al.  Validation of ICD-9-CM Diagnostic Codes for Inflammatory Bowel Disease Among Veterans , 2010, Digestive Diseases and Sciences.